NASDAQ:PLUR Pluri (PLUR) Stock Price, News & Analysis → Trump’s last act as President (From Porter & Company) (Ad) Free PLUR Stock Alerts $5.37 -0.23 (-4.11%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$5.21▼$5.6050-Day Range$4.90▼$8.1652-Week Range$3.45▼$8.56Volume21,387 shsAverage Volume24,798 shsMarket Capitalization$27.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Pluri alerts: Email Address Ad Banyan Hill PublishingREAD THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”Click on Adam's shiny forehead for more details. About Pluri Stock (NASDAQ:PLUR)Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.Read More PLUR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PLUR Stock News HeadlinesApril 11, 2024 | msn.comPackers will face the Eagles in Brazil's first NFL game everApril 10, 2024 | uk.investing.comPluri Inc. announces breakthrough in immune cell therapy productionMay 1, 2024 | Porter & Company (Ad)Trump just won 2024President Trump signed an executive order that ensures he’ll be remembered as one of America’s greatest Presidents. It was an Executive Order that received almost no media attention…April 8, 2024 | msn.comPluri stock jumps 9% on US patent for immune cell productionApril 8, 2024 | globenewswire.comBreakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New MethodApril 3, 2024 | investorplace.comPLUR Stock Earnings: Pluri Reported Results for Q4 2023March 29, 2024 | msn.comReAlta signs deal with NIAID to develop drug for radiation poisoningMarch 28, 2024 | finance.yahoo.comPluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming ConferencesMay 1, 2024 | Porter & Company (Ad)Trump just won 2024President Trump signed an executive order that ensures he’ll be remembered as one of America’s greatest Presidents. It was an Executive Order that received almost no media attention…March 28, 2024 | globenewswire.comPluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming ConferencesMarch 27, 2024 | globenewswire.comPluri Inc. Announces 1-for-8 Reverse Share SplitMarch 21, 2024 | globenewswire.comPluri's Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market ReportMarch 19, 2024 | globenewswire.comEngage with Pluri's Talent: Exciting Conference Appearances AheadMarch 14, 2024 | globenewswire.comPluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug ManufacturingMarch 11, 2024 | globenewswire.comPluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell CultivationMarch 6, 2024 | globenewswire.comPluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory BoardFebruary 28, 2024 | finance.yahoo.comPluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 GoalsFebruary 28, 2024 | globenewswire.comPluri's Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 GoalsFebruary 22, 2024 | msn.comStelmine Secures Minuapan for Further ExplorationFebruary 21, 2024 | msn.comGiant Strides Of Isa Kutepa’s Waltersmith PetromanFebruary 21, 2024 | finance.yahoo.comStelmine increases significantly the length of the gold-bearing corridor at MercatorFebruary 15, 2024 | finance.yahoo.comMeatable Strengthens Board of Directors to Accelerate Growth of Breakthrough Food TechnologyFebruary 14, 2024 | finance.yahoo.comPluri Second Quarter 2024 Earnings: US$0.12 loss per share (vs US$0.24 loss in 2Q 2023)January 25, 2024 | msn.comIsrael’s cell-based coffee: Sustainable solution to brewing industry challenges?January 23, 2024 | finance.yahoo.comStep into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee CrisisJanuary 10, 2024 | finanznachrichten.dePluri Inc.: Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing OrganizationJanuary 8, 2024 | finance.yahoo.comPluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing OrganizationSee More Headlines Receive PLUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pluri and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/12/2024Today5/01/2024Next Earnings (Estimated)5/14/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PLUR CUSIPN/A CIK1158780 Webpluri-biotech.com Phone972747108600Fax972-74-710-8787Employees123Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,320,000.00 Net Margins-6,708.40% Pretax Margin-6,850.42% Return on Equity-177.94% Return on Assets-49.60% Debt Debt-to-Equity Ratio3.69 Current Ratio7.12 Quick Ratio7.12 Sales & Book Value Annual Sales$290,000.00 Price / Sales99.85 Cash FlowN/A Price / Cash FlowN/A Book Value$2.97 per share Price / Book1.88Miscellaneous Outstanding Shares5,180,000Free Float3,925,000Market Cap$28.96 million OptionableOptionable Beta1.45 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Yaacov Yanay (Age 53)President, CEO & Director Comp: $575.93kMs. Chen Franco-Yehuda (Age 40)CFO, Treasurer & Secretary Comp: $375.24kMr. Lior RavivChief Technology OfficerMs. Efrat Livne-HadassVice President of Human ResourcesDr. Nitsan Halevy M.D.Chief Medical OfficerMr. Nimrod Bar ZviChief Commercial OfficerMore ExecutivesKey CompetitorsAchilles TherapeuticsNASDAQ:ACHLCASI PharmaceuticalsNASDAQ:CASIBrainstorm Cell TherapeuticsNASDAQ:BCLICortexymeNASDAQ:CRTXIN8bioNASDAQ:INABView All Competitors PLUR Stock Analysis - Frequently Asked Questions How have PLUR shares performed in 2024? Pluri's stock was trading at $4.6360 on January 1st, 2024. Since then, PLUR stock has increased by 15.8% and is now trading at $5.37. View the best growth stocks for 2024 here. Are investors shorting Pluri? Pluri saw a increase in short interest in April. As of April 15th, there was short interest totaling 35,400 shares, an increase of 176.6% from the March 31st total of 12,800 shares. Based on an average daily volume of 29,700 shares, the days-to-cover ratio is presently 1.2 days. Approximately 0.9% of the company's shares are sold short. View Pluri's Short Interest. When is Pluri's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our PLUR earnings forecast. How were Pluri's earnings last quarter? Pluri Inc. (NASDAQ:PLUR) posted its quarterly earnings results on Monday, February, 12th. The company reported ($0.96) EPS for the quarter. The firm had revenue of $0.11 million for the quarter. Pluri had a negative net margin of 6,708.40% and a negative trailing twelve-month return on equity of 177.94%. When did Pluri's stock split? Pluri's stock reverse split on the morning of Monday, April 1st 2024. The 1-8 reverse split was announced on Monday, April 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. How do I buy shares of Pluri? Shares of PLUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PLUR) was last updated on 5/1/2024 by MarketBeat.com Staff From Our PartnersElon’s New Device is About to Shock the WorldInvestorPlace😱 This phenomenon is smashing regular market gainsMillPubYour bank is lying to you.MyBankTrackerDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersForget Nvidia. This is the future of AIPorter & CompanyBiden out June 13; Kamala won’t replace him?Paradigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
